C4 Therapeutics has been launched by the Dana-Farber Cancer Institute with series A funding from investors including Roche, Novartis and Kraft.
US-based drug developer C4 Therapeutics raised $73m in a series A round yesterday from a consortium of investors including pharmaceutical firms Roche and Novartis. as well as diversified conglomerate Kraft.
The round was led by Cobro Ventures and also featured Cormorant Asset Management, EG Capital Group and assorted angel investors.
C4 is developing treatments that target disease-causing proteins which have proven resistant to current drugs.
The company was spun out of Dana-Farber Cancer Institute, an affiliate of Harvard University’s Harvard…
